Ascendis Pharma Reports Five-Year Kidney Function Gains With TransCon PTH in Hypoparathyroidism Trials
at www.tipranks.com (Mon, 26-Oct 4:27 PM)
Morgan Stanley Sticks to Their Buy Rating for Ascendis Pharma (ASND)
at www.tipranks.com (Mon, 26-Oct 9:15 AM)
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), Ascendis Pharma (ASND) and Amgen (AMGN)
at www.tipranks.com (Sun, 25-Oct 8:20 PM)
